TGFBR3 Antibody

What is TGFBR3 and why is it significant in biomedical research?

TGFBR3 (Transforming Growth Factor Beta Receptor 3), also known as betaglycan, is a transmembrane proteoglycan that functions as a co-receptor for TGF-β signaling. It plays crucial roles in regulating diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis. TGFBR3 has significant research importance due to its involvement in:

• Autoimmune disease pathogenesis, particularly in SLE and experimental autoimmune encephalomyelitis

• Cancer progression and tumor immunotherapy

• Kidney diseases, especially membranous lupus nephritis (MLN)

• T cell function regulation and immune response modulation

The receptor consists of a large extracellular domain (containing heparan sulfate and chondroitin sulfate glycosaminoglycans), a transmembrane region, and a 42-43 amino acid cytoplasmic domain. TGFBR3 binds various TGF-β family ligands, with highest affinity for TGF-β2, serving to "present" these ligands to type I and II TGF-β receptors or limit their availability through proteolytic release .

What are the most effective methods for detecting TGFBR3 in tissue samples?

For effective TGFBR3 detection in tissue samples, immunohistochemistry (IHC) with validated anti-TGFBR3 antibodies has proven most reliable. The method requires:

• Tissue preparation: Standard formalin fixation and paraffin embedding protocols

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer

• Primary antibody incubation: Use of validated anti-TGFBR3 antibodies (typically targeting the extracellular domain)

• Detection system: HRP-conjugated secondary antibodies with DAB visualization

• Colocalization studies: For research on immune-related pathologies, dual immunofluorescence with IgG is recommended

In studies examining TGFBR3-associated membranous nephropathy, researchers successfully used confocal microscopy to evaluate colocalization with IgG within glomerular immune deposits. This approach was instrumental in establishing TGFBR3 as a novel biomarker in a subset of patients with membranous lupus nephritis, showing a 6% prevalence in MLN cases while being absent in non-lupus membranous nephropathy .

How do you optimize Western blot protocols for TGFBR3 detection?

Optimizing Western blot protocols for TGFBR3 detection requires special considerations due to its high molecular weight (280-330 kDa) and extensive post-translational modifications. Follow these research-validated recommendations:

• Sample preparation:

  • Use RIPA or NP-40 based lysis buffers with protease inhibitors

  • Avoid excessive heating of samples (≤70°C for 5 minutes)

• Gel electrophoresis:

  • Use low percentage (7.5%) SDS-PAGE gels to properly resolve high molecular weight proteins

  • Run at lower voltage (80-100V) to prevent smearing

• Transfer:

  • Employ wet transfer methods for large proteins

  • Extended transfer times (overnight at 30V at 4°C) improve efficiency

  • Use 0.45μm PVDF membranes (not nitrocellulose)

• Antibody selection and dilution:

  • Primary antibodies against the extracellular domain work best (1:500-1:1000 dilution)

  • Include positive controls such as recombinant TGFBR3 or known expressing cell lines

  • HRP-conjugated secondary antibodies typically at 1:2000-1:5000 dilution

• Signal detection:

  • Enhanced chemiluminescence (ECL) systems are preferred

  • Longer exposure times may be necessary due to variable expression levels

Researchers should note that TGFBR3 appears as a smear rather than a distinct band due to its extensive glycosylation pattern .

How can TGFBR3 antibodies be used to investigate T cell pathogenicity in autoimmune disease models?

TGFBR3 antibodies are valuable tools for studying T cell pathogenicity in autoimmune disease models, particularly in experimental autoimmune encephalomyelitis (EAE). A methodological approach includes:

• Flow cytometric analysis:

  • Use PE-conjugated anti-TGFBR3 antibodies to monitor differential expression across T cell subsets

  • Combine with markers for T cell subpopulations (CD4, CD8, Foxp3, etc.)

  • Analyze expression during T cell activation and differentiation phases

• Functional studies with T cell-specific TGFBR3 knockout models:

  • Generate conditional Tgfbr3^fl/fl mice with T cell-specific Cre expression

  • Verify deletion efficiency through antibody-based detection methods

  • Compare wild-type and knockout T cell responses in various polarizing conditions

• Ex vivo analysis of pathogenic T cells:

  • Isolate CNS-infiltrating T cells from EAE models

  • Characterize TGFBR3 expression in relation to pathogenic cytokine production (IFNγ, IL-17)

  • Perform adoptive transfer experiments using cells sorted based on TGFBR3 expression

Research has demonstrated that TβRIII functions as a key checkpoint in controlling the pathogenicity of autoreactive T cells in neuroinflammation, particularly through regulating plasticity of Th17 cells into pathogenic Th1 cells. TβRIII null mice developed more severe autoimmune central nervous neuroinflammatory disease after immunization with MOG_35-55, with expanded numbers of CNS infiltrating IFNγ+ CD4+ T cells and cells co-expressing both IFNγ and IL-17 .

What are the methodological considerations when using TGFBR3 antibodies for investigating its role in cancer progression?

When investigating TGFBR3's role in cancer progression using antibodies, researchers should implement these methodological approaches:

• Expression analysis across cancer types and stages:

  • Use IHC on tissue microarrays with validated antibody concentrations

  • Quantify expression using digital pathology and scoring systems

  • Correlate with clinical parameters and survival outcomes

• Functional characterization in cancer cell models:

  • Combine antibody-based detection with genetic manipulation (overexpression/knockdown)

  • Monitor effects on proliferation, migration, invasion, and apoptosis

  • Analyze downstream signaling pathway alterations

• Tumor microenvironment investigations:

  • Use multiplex immunofluorescence to assess TGFBR3 expression in different cell types

  • Evaluate co-localization with immune cell markers

  • Correlate with inflammatory or immunosuppressive signatures

• Soluble versus membrane-bound TGFBR3 characterization:

  • Use domain-specific antibodies to distinguish forms

  • Implement ELISA to quantify soluble TGFBR3 in biological fluids

  • Assess cellular responses to recombinant soluble TGFBR3

Research has shown complex, context-dependent roles for TGFBR3 in cancer. In some contexts, TGFBR3 overexpression induces apoptosis in cancer cells (as demonstrated in nasopharyngeal carcinoma), while in other scenarios, TGFBR3 downregulation generates an immunotolerant microenvironment that may facilitate tumor escape from immunosurveillance .

How can TGFBR3 antibodies be used to study its interaction with other TGF-β signaling components?

For studying TGFBR3's interactions with other TGF-β signaling components, researchers should implement these antibody-based methodological approaches:

• Co-immunoprecipitation (Co-IP) studies:

  • Use anti-TGFBR3 antibodies to pull down receptor complexes

  • Immunoblot for associated proteins (TGFBR1, TGFBR2, BMPRs, β-arrestin2/ARRB2)

  • Include crosslinking steps for transient interactions

  • Control for specificity with isotype antibodies and TGFBR3-null cells

• Proximity ligation assays (PLA):

  • Utilize pairs of antibodies against TGFBR3 and potential binding partners

  • Visualize protein-protein interactions with subcellular resolution

  • Quantify interaction signals under different stimulation conditions

• FRET/BRET-based interaction studies:

  • Combine antibody validation with fluorescent protein tagging approaches

  • Monitor real-time interactions in living cells

  • Assess effects of ligand stimulation on receptor complex formation

• Domain-specific antibodies for structure-function analysis:

  • Map interaction domains using antibodies targeting specific TGFBR3 regions

  • Evaluate functional consequences of blocking specific domains

  • Correlate with mutagenesis studies

TGFBR3 initiates BMP, inhibin, and TGF-beta signaling pathways by interacting with different ligands including TGFB1, BMP2, BMP5, BMP7, or GDF5. It also acts as a cell surface co-receptor for BMP ligands, serving to enhance ligand binding by differentially regulating BMPR1A/ALK3 and BMPR1B/ALK6 receptor trafficking .

How can TGFBR3 antibodies be utilized in diagnosing membranous lupus nephritis?

TGFBR3 antibodies have emerged as valuable diagnostic tools for membranous lupus nephritis (MLN), with specific methodological considerations:

• Immunohistochemical staining protocol:

  • Use formalin-fixed, paraffin-embedded kidney biopsy tissue sections

  • Implement validated anti-TGFBR3 antibodies targeting the extracellular domain

  • Establish standardized scoring systems for positivity

  • Include appropriate controls (non-lupus MN, other forms of glomerulonephritis)

• Co-localization with immune deposits:

  • Perform dual immunofluorescence staining for TGFBR3 and IgG

  • Use confocal microscopy to evaluate precise localization within glomeruli

  • Assess co-localization with other immune reactants (C3, C1q, IgA, IgM)

• Correlation with clinical parameters:

  • Document comprehensive clinical data including:

    • Laboratory parameters (creatinine, proteinuria, autoantibody profiles)

    • Response to therapy

    • Disease progression

Research has established that TGFBR3-associated MN represents a distinct form of membranous nephropathy substantially enriched in patients with lupus. In a comprehensive study, TGFBR3 was not detected in any of 104 consecutive MN cases without clinical evidence of SLE but showed a 6% prevalence in MLN (11 of 199 cases). The clinical significance lies in the fact that identification of TGFBR3-associated MN should alert clinicians to search for an underlying autoimmune disease .

What are the technical challenges in developing ELISA-based detection systems for soluble TGFBR3?

Developing reliable ELISA systems for soluble TGFBR3 detection presents several technical challenges that researchers must address:

• Antibody pair selection and optimization:

  • Screen multiple antibody combinations targeting different epitopes

  • Select pairs with minimal steric hindrance when binding simultaneously

  • Evaluate monoclonal versus polyclonal approaches for capture and detection

  • Optimize antibody concentrations through checkerboard titrations

• Sample preparation considerations:

  • Evaluate matrix effects from different biological fluids (serum, plasma, tissue homogenates)

  • Determine optimal sample dilutions to minimize interference

  • Implement appropriate blocking reagents to reduce background

• Reference standard challenges:

  • Select appropriate recombinant TGFBR3 standards (glycosylated vs. non-glycosylated)

  • Establish consistent standard curves across batches

  • Address molecular weight heterogeneity due to variable glycosylation

• Assay validation parameters:

  • Determine detection limits and quantitative range

  • Assess intra-assay (CV <8%) and inter-assay (CV <10%) precision

  • Evaluate specificity through competitive inhibition tests

  • Perform spike-recovery experiments to assess accuracy

• Biological interpretation:

  • Establish normal reference ranges in healthy populations

  • Correlate with known disease states and progression

  • Compare with membrane-bound TGFBR3 levels when possible

Current ELISA approaches employ the sandwich enzyme immunoassay technique, with pre-coated plates containing anti-TGFBR3 antibodies that capture the protein from biological samples, followed by detection with biotinylated antibodies and visualization through HRP-streptavidin conjugate systems .

How can researchers validate the specificity of anti-TGFBR3 antibodies?

Rigorous validation of anti-TGFBR3 antibody specificity is essential for generating reliable research data. Implement these methodological approaches:

• Genetic validation approaches:

  • Test antibodies on TGFBR3 knockout/knockdown cells or tissues

  • Compare with corresponding wild-type samples

  • Verify signal reduction/elimination in knockout models

  • Implement rescue experiments with TGFBR3 re-expression

• Peptide competition assays:

  • Pre-incubate antibodies with immunizing peptides or recombinant TGFBR3

  • Demonstrate dose-dependent signal reduction

  • Include irrelevant peptides as negative controls

• Multiple antibody concordance:

  • Compare staining patterns using antibodies against different TGFBR3 epitopes

  • Verify consistent localization and expression patterns

  • Document concordance across different detection methods

• Mass spectrometry validation:

  • Perform immunoprecipitation using anti-TGFBR3 antibodies

  • Confirm target identity through mass spectrometry

  • Analyze for presence of anticipated post-translational modifications

• Cross-reactivity assessment:

  • Test against closely related proteins (other TGF-β receptors)

  • Evaluate species cross-reactivity if working across model systems

  • Document any off-target binding

In mass spectrometry-based validation studies for TGFBR3-associated membranous nephropathy, researchers used both laser capture microdissection for glomerular protein enrichment and immunoprecipitation to verify that TGFBR3 co-immunoprecipitated with IgG from kidney biopsy tissue, confirming antibody specificity and target relevance .

What factors affect the reproducibility of flow cytometry experiments using TGFBR3 antibodies?

Achieving reproducible flow cytometry results with TGFBR3 antibodies requires attention to several critical factors:

• Sample preparation variables:

  • Cell isolation methods (enzymatic vs. mechanical dissociation)

  • Fixation protocols (PFA concentration and duration)

  • Permeabilization requirements for intracellular epitopes

  • Fresh vs. frozen samples (viability impact on surface expression)

• Antibody titration and conjugation:

  • Optimal antibody concentration determination through titration curves

  • Fluorophore selection based on expression level (bright fluorophores for low expression)

  • Direct vs. indirect labeling approaches

  • Fluorophore stability and susceptibility to photobleaching

• Instrument considerations:

  • Consistent PMT voltage settings between experiments

  • Regular quality control with standardized beads

  • Compensation matrix verification for multicolor panels

  • Laser alignment and performance monitoring

• Biological variables affecting TGFBR3 expression:

  • Activation state of cells (particularly for T lymphocytes)

  • Culture conditions prior to analysis

  • Cell cycle phase

  • Exposure to TGF-β ligands (potential receptor internalization)

• Gating strategy standardization:

  • Consistent live/dead discrimination

  • Standardized population identification markers

  • Matched isotype controls for threshold setting

  • Use of fluorescence-minus-one (FMO) controls

In flow cytometric detection of TGFBR3 on human blood lymphocytes, researchers have successfully used PE-conjugated anti-TGFBR3 antibodies with careful comparison to isotype controls. The detailed protocols for staining membrane-associated proteins include optimization steps for blocking, antibody concentration, and incubation conditions to ensure reproducible detection across different cell types such as peripheral blood lymphocytes and MCF-7 breast cancer cell lines .

How might TGFBR3 antibodies be utilized to develop targeted therapeutic approaches?

The development of TGFBR3-targeted therapeutic approaches using antibodies represents an emerging research direction with several methodological considerations:

• Therapeutic antibody design strategies:

  • Domain-specific targeting to modulate specific functions

  • Development of function-blocking vs. agonistic antibodies

  • Humanization of mouse antibodies for clinical translation

  • Fragment-based approaches (Fab, scFv) for improved tissue penetration

• Functional screening approaches:

  • In vitro assays measuring TGF-β pathway modulation

  • Cell-based phenotypic screens (proliferation, migration, apoptosis)

  • Binding affinity and specificity characterization

  • Assessment of effects on soluble vs. membrane-bound forms

• Disease-specific applications:

  • Cancer immunotherapy: Antibodies targeting TGFBR3 could enhance anti-tumor immune responses by modulating the immunosuppressive microenvironment

  • Autoimmune diseases: Modulating TGFBR3 function on pathogenic T cells could reduce neuroinflammation in MS/EAE models

  • Fibrotic disorders: Targeting TGFBR3 might influence pro-fibrotic TGF-β signaling

• Biomarker-guided therapeutic applications:

  • Use of soluble TGFBR3 levels as predictive biomarkers for immunotherapy response

  • Development of companion diagnostics for patient stratification

Research has indicated that TGFBR3 downregulation generates an immunotolerant microenvironment, suggesting that TGF-β inhibition strategies could enhance tumor immunotherapy efficacy. Additionally, studies have shown that soluble TGFBR3 levels might serve as predictive biomarkers for immunotherapy response, expanding the mechanisms by which TGFBR3 suppresses cancer progression to include effects on the tumor immune microenvironment .

What novel approaches are being developed to study TGFBR3 post-translational modifications using antibody-based methods?

Investigating TGFBR3 post-translational modifications (PTMs) using antibody-based methods involves several innovative approaches:

• PTM-specific antibody development:

  • Generation of antibodies recognizing specific glycosylation patterns

  • Development of phospho-specific antibodies targeting cytoplasmic domain sites

  • Antibodies against proteolytically processed forms (membrane-bound vs. soluble)

  • Validation using synthetic peptides with defined modifications

• Advanced proteomics integration:

  • Immunoprecipitation followed by mass spectrometry (IP-MS)

  • Coupling with glycoproteomics workflows

  • Quantitative comparison of modification states across conditions

  • Cross-linking mass spectrometry to map interaction interfaces

• Single-molecule imaging approaches:

  • Super-resolution microscopy with PTM-specific antibodies

  • Tracking of receptor dynamics and clustering based on modification state

  • Correlative light and electron microscopy for nanoscale localization

• Functional consequence assessment:

  • Correlation of specific modifications with signaling outcomes

  • Site-directed mutagenesis of modification sites

  • Structure-function analyses with domain-specific antibodies

TGFBR3 undergoes extensive post-translational modifications, particularly glycosylation, resulting in a protein that migrates at 280-330 kDa on gel electrophoresis despite its core protein being significantly smaller. The receptor contains heparan sulfate and chondroitin sulfate glycosaminoglycans along with five potential N-linked glycosylation sites. These modifications likely influence its ligand binding properties and interactions with other receptors, making them important targets for investigation .

How can TGFBR3 antibodies be integrated into multiplexed imaging systems for studying the tumor microenvironment?

Integrating TGFBR3 antibodies into multiplexed imaging systems for tumor microenvironment studies requires sophisticated methodological approaches:

• Multiplexed immunofluorescence optimization:

  • Antibody panel design incorporating TGFBR3 with immune cell markers

  • Sequential staining protocols with tyramide signal amplification

  • Validation of antibody performance in multiplexed context

  • Optimization of stripping/quenching between rounds

• Mass cytometry imaging (IMC) implementation:

  • Metal-conjugation of TGFBR3 antibodies for CyTOF-based imaging

  • Panel design with up to 40 markers simultaneously

  • Spatial analysis of TGFBR3 expression relative to immune cell populations

  • Correlation with clinical outcomes

• Digital spatial profiling approaches:

  • Integration of TGFBR3 antibodies with NanoString DSP technology

  • Region-of-interest selection based on TGFBR3 expression patterns

  • Quantitative spatial analysis of protein and RNA expression

  • Computation of spatial relationship metrics

• Image analysis and quantification:

  • Cell segmentation strategies for membrane proteins

  • Quantitative assessment of co-localization with other markers

  • Spatial statistics for neighborhood analysis

  • Machine learning approaches for pattern recognition

• Validation and clinical correlation:

  • Correlation with conventional IHC on consecutive sections

  • Integration with genomic and transcriptomic data

  • Assessment of prognostic/predictive value

  • Comparison across tumor types and treatment responses